一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括Trastuzumab deruxtecan，当前状态为研究进行中，已停止招募。登记地点显示中国Duarte、Santa Rosa、Chicago、Muncie等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Trastuzumab deruxtecan · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Research Site · Duarte
- Research Site · Santa Rosa
- Research Site · Chicago
- Research Site · Muncie
- Research Site · Boston
- Research Site · Middletown
- Research Site · Harrison
- Research Site · New York
- Research Site · Durham
- Research Site · Houston
- Research Site · Seattle
- Research Site · Auchenflower
- Research Site · Blacktown
- Research Site · Camperdown
- Research Site · Heidelberg
- Research Site · Melbourne
- Research Site · Nedlands
- Research Site · Brussels
- Research Site · Leuven
- Research Site · Liège
- Research Site · Porto Alegre
- Research Site · São Paulo
- Research Site · Vitória
- Research Site · Kelowna
- Research Site · Ottawa
- Research Site · Québec
- Research Site · Montreal
- Research Site · Brno
- Research Site · Hradec Králové
公开的入选条件
- * Locally advanced, unresectable, or metastatic disease based on most recent imaging.
- * Part 1:The respective cohorts for patient inclusion are:
- Cohort 1: Biliary tract cancer
- Cohort 2: Bladder cancer
- Cohort 3: Cervical cancer
- Cohort 4: Endometrial cancer
- Cohort 5: Epithelial ovarian cancer
- Cohort 6: Pancreatic cancer
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04482309；登记信息更新于 2026-07-10。